Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.”
An Oregon Health & Science University researcher is among an international team closing in on why many people with schizophrenia and other psychotic disorders are "supersensitive" to the powerful neurotransmitter dopamine.
A new brain imaging study of recently diagnosed schizophrenia patients has found, for the first time, that the loss of gray matter typically experienced by patients can be prevented by one of the new atypical antipsychotic drugs, olanzapine, but not by haloperidol, an older, conventional drug.
After a first psychotic episode, patients who were treated with an atypical antipsychotic medication had less change in brain volume compared with patients treated with a conventional antipsychotic medication, according to an article in the April issue of Archives of General Psychiatry.
Quetiapine, a drug commonly used in nursing homes to treat agitation and related symptoms in people with Alzheimers' disease actually worsens patients' illness, speeding up their rate of decline significantly, says a paper published on bmj.com.
Researchers at UT Southwestern Medical Center have discovered that drugs commonly used to treat psychiatric illnesses and blood disorders in humans may protect the brain cells that die in people with Huntington's disease, possibly delaying the onset and slowing the progression of the disease.
Generic antipsychotic drugs can protect brain cells from a virus that causes a fatal nervous system disorder, according to research conducted at Brown University and Case Western Reserve University.
The researchers studied the brain waves of normal and schizophrenic patients as they responded to images. Those with the disorder showed no electrical activity in a certain frequency-the “gamma” range, from 30 to 100 brain waves per second-that healthy brain cells use to exchange information about the environment and form mental impressions.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
Researchers from the Johns Hopkins Children's Center say a group of drugs known as "atypical antipsychotics" that are commonly used to treat children with aggression, bipolar disorder, and schizophrenia may trigger insulin resistance, a condition that increases the risk of developing Type 2 diabetes and heart disease later in life.
AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
Janssen Pharmaceutica, the maker of RISPERDAL® (risperidone), the most frequently prescribed antipsychotic medication in the U.S., has sent a letter to health care providers to clarify the risks involved with the use of RISPERDAL®.
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
A member of a class of drugs that are widely prescribed for abnormal behavioral symptoms in Alzheimer’s – but not often studied in people with the degenerative brain disease – proved to be effective and well tolerated in treating agitation in people with severe Alzheimer’s
Scientists funded by the UK's largest biomedical research charity, The Wellcome Trust, have developed a drink that enhances the effectiveness of medication given to treat psychiatric illnesses such as mania and schizophrenia.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Patients with schizophrenia who fail to take their medicines as prescribed are over one-and-a-half times as likely to be rehospitalised and use in-patient services as patients who stick to their medication regimen. Non-adherence predicted an excess annual cost per patient of £5000 for total service use.
Patients with severe and persistent mental illness treated with antipsychotic medications reported positive changes in diet, exercise, stress management, improved sleep, and increased confidence in maintaining these lifestyle changes after participating in the Solutions for Wellness Personalized Program (SFWPP), new data show.
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.